Sign up to save your podcasts
Or
Share 1: Post Brexit landscape for the pharmaceutical industry
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
1: Post Brexit landscape for the pharmaceutical industry
Meeting the regulatory challenges of the post-Brexit pharma landscape
In the inaugural PharmaLex Talks podcast, host Elizabeth Hunt chats with Charley Maxwell, Director QMC / Senior Consultant at Pharmalex about the post-Brexit Pharma landscape.
Their wide-ranging conversation covers many key issues including; the cost of Brexit to the Pharma industry so far, what have been, and what are foreseen to be the biggest challenges to come, how UK manufacturers are coping, the Northern Ireland Protocol, and more.
View all episodes
By PharmaLex TalksMeeting the regulatory challenges of the post-Brexit pharma landscape
In the inaugural PharmaLex Talks podcast, host Elizabeth Hunt chats with Charley Maxwell, Director QMC / Senior Consultant at Pharmalex about the post-Brexit Pharma landscape.
Their wide-ranging conversation covers many key issues including; the cost of Brexit to the Pharma industry so far, what have been, and what are foreseen to be the biggest challenges to come, how UK manufacturers are coping, the Northern Ireland Protocol, and more.
More shows like PharmaLex Talks
View all
WSJ What’s News
4,332 Listeners